Biocept to Present at Four Virtual Investor Conferences in September
September 07 2021 - 8:00AM
Business Wire
Biocept (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays and services, announces that Michael Nall,
President and CEO, will present at four upcoming investor
conferences as follows:
- H.C. Wainwright 23rd Annual Global Investment Conference
being held September 13-15, 2021. The presentation can be accessed
on the Investor Relations section of the Biocept website beginning
Monday, September 13, 2021 at 4:00 a.m. Eastern time (1:00 a.m.
Pacific time).
- Oppenheimer Fall Healthcare Life Sciences & MedTech
Conference on Wednesday, September 22, 2021 at 3:45 p.m.
Eastern time (12:45 p.m. Pacific time).
- Cantor Virtual Healthcare Conference on Wednesday,
September 29, 2021 at 4:40 p.m. Eastern time (1:40 p.m. Pacific
time).
- Benzinga Healthcare Small Cap Conference on Thursday,
September 30, 2021 at 2:20 p.m. Eastern time (11:20 a.m. Pacific
time). The presentation will be available on the Benzinga website
here.
Webcasts of the presentations at the Oppenheimer and Cantor
conferences will be available on the Events and Presentations page
of the Biocept website and will be archived for 90 days.
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210907005034/en/
Investors: Jody Cain, LHA Investor Relations Jcain@lhai.com,
310-691-7100
Media: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024